UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED

<p><strong>1. INDICATIONS AND USAGE</strong></p> <p>BONJESTA is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.</p> <p><strong>Limitations of Use</strong></p> <p>BONJESTA has not been studied in women with hyperemesis gravidarum.</p>

**1\. What Maxigesic PE is and what it is used for** Maxigesic PE contains 500 mg paracetamol, 150 mg ibuprofen and 2.5 mg phenylephrine hydrochloride in each tablet dose. Paracetamol works to stop the pain messages from getting through to the brain. It also acts to reduce fever. Ibuprofen belongs to a group of medicines called non-steroidal anti-inflammatory drugs (or NSAIDs). It relieves pain and reduces inflammation (swelling, redness or soreness). Phenylephrine hydrochloride acts as a decongestant to reduce mucosal lining swelling and suppress the production of mucus. Maxigesic PE is used for temporary relief of cold and flu symptoms including: - Headache - Fever - Pain - Nasal congestion Ask your doctor or pharmacist if you have any questions about this medicine. You must talk to a doctor if you do not feel better or if you feel worse after 3 days.

<p>Therapeutic indications</p> <p><em><strong>Treatment of influenza</strong></em></p> <p>In patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. This indication is based on clinical studies of naturally occurring influenza in which the predominant infection was influenza A (see Pharmacodynamic properties &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p>Based on limited pharmacokinetic and safety data, Oseltamivir Capsules can be used in children 6 to 12 months of age for treatment during a pandemic influenza outbreak. The treating physician should take into account the pathogenicity of the circulating strain and the underlying condition of the patient to ensure there is a potential benefit to the child.</p> <p><em><strong>Prevention of influenza</strong></em></p> <ul class="dash"> <li>Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.</li> <li>The appropriate use of Oseltamivir Capsules for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g., in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.</li> </ul> <p><em><u><strong>Oseltamivir Capsules is not a substitute for influenza vaccination.</strong></u></em><br> The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Decisions regarding the use of antivirals for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses and the impact of the disease in different geographical areas and patient populations.</p>

<p>Therapeutic indications</p> <p><em><strong>Treatment of influenza</strong></em></p> <p>In patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. This indication is based on clinical studies of naturally occurring influenza in which the predominant infection was influenza A (see Pharmacodynamic properties &ndash; <em>please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information</em>).</p> <p>Based on limited pharmacokinetic and safety data, Oseltamivir Capsules can be used in children 6 to 12 months of age for treatment during a pandemic influenza outbreak. The treating physician should take into account the pathogenicity of the circulating strain and the underlying condition of the patient to ensure there is a potential benefit to the child.</p> <p><em><strong>Prevention of influenza</strong></em></p> <ul class="dash"> <li>Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.</li> <li>The appropriate use of Oseltamivir Capsules for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g., in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.</li> </ul> <p><em><u><strong>Oseltamivir Capsules is not a substitute for influenza vaccination.</strong></u></em><br> The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Decisions regarding the use of antivirals for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses and the impact of the disease in different geographical areas and patient populations.</p>

Therapeutic indications _**Treatment of influenza**_ In patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. This indication is based on clinical studies of naturally occurring influenza in which the predominant infection was influenza A (see Pharmacodynamic properties – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Based on limited pharmacokinetic and safety data, Oseltamivir Capsules can be used in children 6 to 12 months of age for treatment during a pandemic influenza outbreak. The treating physician should take into account the pathogenicity of the circulating strain and the underlying condition of the patient to ensure there is a potential benefit to the child. _**Prevention of influenza**_ - Post-exposure prevention in individuals one year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. - The appropriate use of Oseltamivir Capsules for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g., in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older. _**Oseltamivir Capsules is not a substitute for influenza vaccination.**_ The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Decisions regarding the use of antivirals for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses and the impact of the disease in different geographical areas and patient populations.

<p><strong>4.1. Therapeutic indications</strong><br> Letrozole is not indicated in hormone receptor-negative disease.</p> <p>Letrozole is indicated in:</p> <ul> <li><p>Adjuvant treatment of postmenopausal women with hormone receptor-positive invasive early breast cancer.</p></li> <li><p>Extended adjuvant treatment of invasive early breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for five years.</p></li> <li><p>First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.</p></li> <li><p>Treatment of advanced breast cancer after relapse or progression of the disease in women with natural or artificially induced postmenopausal endocrine state, who have been previously treated with anti-estrogens.</p></li> </ul>

<p><strong>INDICATIONS</strong><br> Fluimucil&reg; A Effervescent Tablets 600mg and Fluimucil&reg; Granules 600mg are indicated as an adjuvant treatment in certain clinical condition characterized by the presence of thick and viscous mucoid or mucopurulent secretions such as:</p> <ul class="dash"> <li>Chronic bronchopulmonary diseases (chronic obstructive pulmonary disease, emphysema with bronchitis, chronic asthmatic bronchitis, bronchiectasis);</li> <li>Acute bronchopulmonary diseases (asthma with bronchial mucus plugging, bronchitis, bronchopneumonia, tracheobronchitis, bronchiolitis, pulmonary complications of cystic fibrosis, pulmonary complications associated with surgery).</li> </ul>

<p><strong>INDICATIONS</strong><br> Helps to reduce the risk of antibiotic-associated diarrhea in adults.</p>